IPSEN (OTCMKTS:IPSEY) is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin). In neuroscience, Ipsen markets botulinum toxin therapies under the Dysport brand, indicated for movement disorders and spasticity. The rare disease pipeline features lanreotide, marketed as Somatuline, for neuroendocrine tumors and acromegaly. Ipsen invests heavily in research and development, leveraging a global network of laboratories to advance novel therapeutic modalities.
Ipsen operates in more than 100 countries across Europe, North America, Latin America, Asia-Pacific and the Middle East, with significant manufacturing and R&D sites in France, the United States and Ireland. The company collaborates with academic institutions, biotech partners and patient advocacy groups to accelerate the translation of science into new treatments. Ipsen’s ADR program trades on the OTC Markets under the symbol IPSEY, facilitating access for U.S. investors to its shares.
Under the guidance of an experienced management team based at its Paris region headquarters, Ipsen continues to expand its global footprint and deepen its expertise in precision medicine. The company remains committed to sustainable growth by balancing commercial performance with reinvestment in innovation and patient-centric initiatives.
